Clinical Trial Update: A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study [Phase 4]

View source ↗

Summary

This document outlines a Phase 4 study providing continued access to mitapivat for participants who previously completed an Agios-sponsored mitapivat trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemolytic Anemia
• Pyruvate Kinase Deficiency

Drugs mentioned

• Pyrukynd (mitapivat)

Snippet

Sponsor: Agios Pharmaceuticals, Inc. | Conditions: Pyruvate Kinase Deficiency, Anemia, Hemolytic | Phase 4 | Status: ENROLLING_BY_INVITATION